Known targets — ChEMBL curated mechanism
ABCC9ABL1ACEACHEACVR1ADORA1ADORA2AADORA2BADORA3ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALOX5ATP4AATP4BBCRBTKCACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGCRBNCUL4ACXCR1CXCR2DDB1DDCDHFRDPP4DRD2DRD3DRD4EGFRERBB2ERBB4ESR1ESR2FDPSFKBP1AFLT1FLT3FLT4GARTGHSRGRIA1GRIA2GRIA3GRIA4GRIK1GRIK2GRIK3GRIK4GRIK5GRIN2AGSK3AGSK3BHDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IDH1IDH2IMPA1ITGA2BITGB3JAK1JAK2JAK3KCNJ11KCNK3KCNK9KDRKITMEN1METMMP1MMP13MMP7MMP8NANOD2NS5bODC1OPG057OPRD1OPRK1OPRM1PPARP1PARP2PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PKLRPPARDPPATPTGS1PTGS2RBX1ROCK1ROCK2RRM1RRM2RRM2BSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC10A2SLC5A2SLC6A2SLC6A3SLC6A4SLC9A3SYKTACR1THRATHRBTOP1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYK2TYMSVDRampCblablaT-3blaT-4blaT-5blaT-6blaUOE-1dacAdacBdacCfolAfolPftsIgyrAgyrBileSmecAmrcAmrcBmrdAparCparEpbp2pbp4pbpApbpFrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUthyAykgMykgO
The experimentally established mechanism targets of Hydrazine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 5/20 | 0.54 |
| ▸ | ST14 | Q9Y5Y6 | 1/20 | 0.53 |
| ▸ | MAOB | P27338 | 2/20 | 0.52 |
| ▸ | LOX | P28300 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | LTA4H | P09960 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1301847 | 0.96 | LOXL2 (0.58) | LOXL2ST14MAOBLOXKDM4E | |
| Hydrochloric Acid SCHEMBL919885 | 0.94 | LOXL2 (0.57) | LOXL2ST14MAOBLOXKDM4E | |
| SCHEMBL4949955 | 0.90 | ST14 (0.58) | LOXL2ST14MAOBLOXALDH1A1 | |
| SCHEMBL27907657 | 0.86 | LOXL2 (0.47) | LOXL2ST14MAOBLOXKDM4E | |
| SCHEMBL29215392 | 0.86 | ALDH1A1 (0.57) | LOXL2ST14MAOBLOXKDM4E | |
| Water SCHEMBL919765 | 0.84 | ST14 (0.53) | LOXL2ST14MAOBLOXALDH1A1 | |
| SCHEMBL12167626 | 0.83 | ALDH1A1 (0.68) | LOXL2ST14MAOBALDH1A1TDP1 | |
| SCHEMBL100121 | 0.81 | LOXL2 (0.52) | LOXL2ST14MAOBLOXALDH1A1 | |
| Water SCHEMBL922874 | 0.81 | MAOB (0.54) | LOXL2ST14MAOB | |
| SCHEMBL922831 | 0.81 | AGXT (0.52) | LOXL2ST14MAOBLOXKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210163476-A1 | IMIDAZOQUINOLYL COMPOUNDS HAVING ANTI-INFLAMMATORY, ANTIFUNGAL, ANTIPARASITIC, AND ANTICANCER ACTIVITY | PHARMA CINQ, LLC | 2021-06-03 | — | — | US | disclosed |
| US-10934284-B2 | Aminoquinazoline compounds having anti-inflammatory, antifungal, antiparasitic, and anticancer activity | WELLSTAT THERAPEUTICS CORPORATION (US) | 2021-03-02 | — | — | US | disclosed |
| EP-3632426-A1 | AMINE COMPOUNDS HAVING ANTI-INFLAMMATORY, ANTIFUNGAL, ANTIPARASITIC AND ANTICANCER ACTIVITY | Wellstat Therapeutics Corporation (US) | 2020-04-08 | — | — | EP | disclosed |
| EP-2950649-B1 | AMINE COMPOUNDS HAVING ANTI-INFLAMMATORY, ANTIFUNGAL, ANTIPARASITIC AND ANTICANCER ACTIVITY | WELLSTAT THERAPEUTICS CORP (US) | 2020-03-04 | — | — | EP | disclosed |
| US-20190194193-A1 | AMINOQUINAZOLINE COMPOUNDS HAVING ANTI-INFLAMMATORY, ANTIFUNGAL, ANTIPARASITIC, AND ANTICANCER ACTIVITY | PHARMA CINQ, LLC | 2019-06-27 | — | — | US | disclosed |
| US-20180298000-A1 | AMINOQUINOLINE COMPOUNDS HAVING ANTICANCER ACTIVITY | PHARMA CINQ, LLC | 2018-10-18 | — | — | US | disclosed |
| US-20150361077-A1 | AMINE COMPOUNDS HAVING ANTI-INFLAMMATORY, ANTIFUNGAL, ANTIPARASITIC, AND ANTICANCER ACTIVITY | PHARMA CINQ, LLC | 2015-12-17 | — | — | US | disclosed |
| EP-2950649-A2 | AMINE COMPOUNDS HAVING ANTI-INFLAMMATORY, ANTIFUNGAL, ANTIPARASITIC AND ANTICANCER ACTIVITY | Wellstat Therapeutics Corporation (US) | 2015-12-09 | — | — | EP | disclosed |
| WO-2014120995-A2 | AMINE COMPOUNDS HAVING ANTI-INFLAMMATORY, ANTIFUNGAL, ANTIPARASITIC AND ANTICANCER ACTIVITY | WELLSTAT THERAPEUTICS CORPORATION (US) | 2014-08-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210163476-A1 | IMIDAZOQUINOLYL COMPOUNDS HAVING ANTI-INFLAMMATORY, ANTIFUNGAL, ANTIPARASITIC, AND ANTICANCER ACTIVITY | NOD1, NLRP3, AADAC | LOXL2 3179/4885ST14 4029/4885MAOB 1777/4885 |
| US-20180298000-A1 | AMINOQUINOLINE COMPOUNDS HAVING ANTICANCER ACTIVITY | MYC, AAAS, ASNS | LOXL2 3436/4885ST14 4008/4885MAOB 1621/4885 |
| US-20190194193-A1 | AMINOQUINAZOLINE COMPOUNDS HAVING ANTI-INFLAMMATORY, ANTIFUNGAL, ANTIPARASITIC, AND ANTICANCER ACTIVITY | AAAS, AADAC, NFKBIA | LOXL2 3505/4885ST14 3270/4885MAOB 1825/4885 |
| US-20150361077-A1 | AMINE COMPOUNDS HAVING ANTI-INFLAMMATORY, ANTIFUNGAL, ANTIPARASITIC, AND ANTICANCER ACTIVITY | AADAC, CASP1, AAAS | LOXL2 3154/4885ST14 3833/4885MAOB 248/4885 |
| US-10934284-B2 | Aminoquinazoline compounds having anti-inflammatory, antifungal, antiparasitic, and anticancer activity | AAAS, AADAC, NFKBIA | LOXL2 3505/4885ST14 3270/4885MAOB 1825/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.